TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02090335

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In SHAPE
Description: In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitness Club Membership
Description: Fitness club membership with education in using the exercise equipment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitness Club Membership
Description: Fitness club membership with education in using the exercise equipment.
Study: NCT01358838

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ablative 10600 nm fractional laser therapy
Description: Half of the scar, or one of two comparable scars, will be treated with the ablative 10600 nm fractional laser. There wil be 3 treatments, with 8 weeks apart.~Half of the scar, or one of two comparable scars, will receive no treatment at all.
Study: NCT02757924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with prebiotics
Description: Sole source nutrition
Study: NCT06243107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai-chi
Description: Participants will each receive a Tai Chi manual and have access to an instructional audio-visual material via a QR code. The instructional material is tailored specifically for cancer patients. Participants will receive individualized guidance and instructions from the researcher (YH) until they have completed all the executions on the checklist to the required standards.
Study: NCT02424409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2: Intervention
Description: 1. The corticoid treatment (Prednisolone or Prednisone) given from the ED for the first day if the patient is discharged at nighttime or during the weekend.~   A detailed prescription including 1) A written prescription of the corticosteroid treatment given orally for a total treatment length of 7 days 2) A written prescription describing the adaptation of the inhaled treatment 3) Peak expiratory flowmeter~2. A written action plan with formalized recommendations for the patient~3. A formal letter and recommendations to the general practitioner including information about the ED visit, and the necessity to program a follow up with regular consultations as well as to program spirometry evaluation for his patient.~   The ED doctor at discharge will explain all these documents orally~4. Recommendations for an early contact with the general practitioner;~5. Telephone call of the emergency department to the patient at day 7 +/-1 in order to ensure the link with the general practitioner.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 1: Control
Description: patients without discharge protocol
Study: NCT04889235

Intervention type: PROCEDURE
Intervention: Major liver resection
Description: All patients undergo Major hepatic resection, differences between sarcopenia and no-sarcopenia groups will be observed

Intervention type: PROCEDURE
Intervention: Major liver resection
Description: All patients undergo Major hepatic resection, differences between sarcopenia and no-sarcopenia groups will be observed
Study: NCT04490135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Description: As described above
Study: NCT04632901

Intervention type: DIAGNOSTIC_TEST
Intervention: VA assessment
Description: The VA of all participants will be evaluated by counting the smallest line that can be read within a time duration greater than or equal to the average reading time of the larger lines minus 2.58 times the SD of the reading time of these lines.~In clinical practice, the VA is the common parameter of VA adding a tolerant time limit to clearly determine the end of the test.

Intervention type: DIAGNOSTIC_TEST
Intervention: CVA assessment
Description: The CVA of all participants will be evaluated by counting the smallest line that can be read within a time duration greater than or equal to the average reading time of the larger lines minus 1.96 times the SD of the reading time of these lines.~In clinical practice, the CVA is the minimum VA that can be read in maximal speed.
Study: NCT00238381

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 5 cm colon-J-pouch
Description: 5 cm colon-J-pouch with/without temporary protective ileostomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: side-to-end anastomosis
Description: side-to-end anastomosis with/without temporary protective ileostomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: straight coloanal anastomosis
Description: straight coloanal anastomosis with/without temporary protective ileostomy
Study: NCT02646215

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threshold inspiratory muscle training
Description: Inspiratory muscle training
Study: NCT00110253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)
Description: S-Caine Peel is composed of a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine, which was applied topically. The S Caine Peel was applied at approximately 1 mm in thickness and remained on the treatment area for 30 or 60 minutes
Study: NCT00844740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood nand urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
Study: NCT01108458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: iv, 840 mg, 420 mg
Study: NCT01866657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasoconstrictor Agents
Description: cerebral desaturations may be treated with IV vasoactives to increase blood pressure or cardiac output at attending physician's descretion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head/neck repositioning
Description: Assure that arterial and venous neck blood flow is not obstructed related to patient positioning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increase ETCO2
Description: Allow normalization or slight increase in end tidal CO2 to cause selective cerebral vasodilation and increased tissue blood flow/O2 delivery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV fluid bolus
Description: Administer IV fluids to increase preload and cardiac output

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Additional anesthesia
Description: By deepening anesthetic there will be a decrease in cerebral metabolic oxygen consumption.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RBC transfusion
Description: By administering RBCs there will be a increase in intravascular volume and cardiac preload and an increase in oxygen carrying capacity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Increase FiO2
Description: Increase FiO2 to improve oxygen delivery to tissue
Study: NCT01046279

Intervention type: DRUG
Intervention: Bevacizumab
Description: Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV) assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons
Study: NCT00552981

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inhalation of warm air in a Finnish sauna
Description: three times on three following days, each 2-3 minutes

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: inhalation of ambient air in a Finnish sauna
Description: three times on three following days, each 2-3 minutes
Study: NCT03194750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Share ultrasound measurement of IVC collapsibility to Nephrology Attending
Description: Nephrology attending will be provided with the respiratory variability of IVC diameter as a percent, in addition to a predefined cutoff for responsiveness to volume resuscitation of \< 12%. The information will be provided before rounds and before the attending sets the fluid removal goals on dialysis for that day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Do not share ultrasound measurement of IVC collapsibility to Nephrology Attending
Description: Respiratory variability of IVC diameter will be measured, but the measurement result will not be shared with the treating team.
Study: NCT01108458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: PO, 150 mg
Study: NCT01716143

Intervention type: PROCEDURE
Group type: OTHER
Intervention: radiofrequency catheter ablation
Study: NCT01402596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 0,4 mg per kg - intranasal midazolam - once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloral Hydrate
Description: 50 mg per kg, rectal
Study: NCT00718822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen concentration in the culture atmosphere

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen concentration in the culture atmosphere
Study: NCT02556437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HyQvia
Description: Human immunoglobulin 10% with recombinant hyaluronidase for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HyQvia
Description: Human immunoglobulin 10% with recombinant hyaluronidase for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcuvia
Description: Human immunoglobulin 16% for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcuvia
Description: Human immunoglobulin 16% for subcutaneous injection
Study: NCT02287350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac potassium oral solution
Description: Administration of diclofenac potassium oral solution, taken by mouth, as needed for mild to moderate acute pain.
Study: NCT06057259

Intervention type: DEVICE
Intervention: Joint position sense measurement
Description: The participants' wrist joint position sense was evaluated.

Intervention type: DEVICE
Intervention: Joint position sense measurement
Description: The participants' wrist joint position sense was evaluated.
Study: NCT01010295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline (tetracycline)
Description: doxycycline 100 mg twice daily for 3 weeks
Study: NCT01597375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh \>60kg or 5 mg by mouth daily if they weigh \<60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh \>60kg or 5 mg by mouth daily if they weigh \<60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel Oral Tablet
Description: Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh \>60kg or 5 mg by mouth daily if they weigh \<60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel Oral Tablet
Description: Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh \>60kg or 5 mg by mouth daily if they weigh \<60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.
Study: NCT03285568

Intervention type: DRUG
Intervention: Palbociclib
Description: Observe patients receiving palbociclib for dose adjustment and lab monitoring
Study: NCT00615862

Intervention type: OTHER
Intervention: Observational study; no interventions
Description: Validated questionnaires will be administered. Blood samples will be analyzed for levels of immune markers as well as cortisol. This is an observational study and patients will not undergo any treatment as part of study participation. Patients will not receive medications or other interventions if they participate in the study. Blood samples analyzed are from samples remaining in the hospital laboratory that were collected as part of routine patient care and destined to be discarded.
Study: NCT00650117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)
Description: single application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duragesic 25 mcg/h + Scotch Duct Tape (3M)
Description: single application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
Description: single application
Study: NCT03594903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video intervention (therapy expectation violation)
Description: The investigators asked experts (psychotherapist and scientists in the area of clinical psychology) about typical therapy expectation violations in therapy and searched the literature for information about typical therapy processes and outcomes. Having these information they designed a script for the experimental video. The patients in the video are played by actors aged from 28 to 58 years (two male and two female actors). Patients are representing common mental disorders (depression, anxiety disorder, alcohol addiction, depression after physical disease). The abbreviated name, age and disorder of the patients is displayed for 3 seconds in the video. The patients are giving information about the mostly positive outcome and the process of their therapy. All participants are watching a video with all patients (7 minutes). The videos (control and experimental group) have been evaluated by 12 experts (psychotherapist and scientists in the area of clinical psychology).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: video intervention (symptoms+ expectation)
Description: Participants in the control group are watching a video with the same patients (actors) as in the experimental video. In this video patients are shown before or after the first therapy session. They are giving information about symptoms and their expectation on therapy but NOT about therapy outcome.
Study: NCT01582789

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enfilcon A
Description: enfilcon A daily wear soft contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enfilcon A
Description: enfilcon A daily wear soft contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: senofilcon A daily wear soft contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: senofilcon A daily wear soft contact lens
Study: NCT03383796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Three dimensional laparoscopic resection for pCCA
Description: Three dimensional laparoscopic resection for pCCA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open resection for pCCA
Description: Open resection for pCCA
Study: NCT01784432

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-level laser therapy and training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Study: NCT04591535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
Description: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
Description: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
Description: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
Description: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
Study: NCT01478711

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Decision Support Tool
Description: A clinical decision support tool embedded within Epic will appear for children with a history of prematurity at the intervention sites.
Study: NCT02790073

Intervention type: DRUG
Group type: OTHER
Intervention: SNF472
Description: SNF472 for calciphylaxis
Study: NCT01811979

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral sucrose solution
Description: Oral sucrose solution plus topical anesthetics

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Steril water
Description: steril water plus topical anesthetics
Study: NCT03328143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lavender (Lavandula angustifolia)
Description: Lavender (Lavandula angustifolia) is an essential oil.
Study: NCT03610737

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MILD Procedure
Description: The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.~Other Name: MILD lumbar decompression

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Management (CMM)
Description: CMM can include physical therapy, home exercise, pain medication, epidural steroid injections, nerve blocks, and other lumbar steroid injections.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Management (CMM)
Description: CMM can include physical therapy, home exercise, pain medication, epidural steroid injections, nerve blocks, and other lumbar steroid injections.
Study: NCT03659253

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral Fluid Based Self Testing
Description: The intervention will introduce provider supervised and unsupervised self-testing as an option for early HIV diagnosis among MSM community in Denpasar Bali Indonesia.
Study: NCT00650117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
Description: single application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)
Description: single application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duragesic 25 mcg/h + Microfoam Tape (3M)
Description: single application
Study: NCT04764370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WeFlow-Ach Moduler Embedded Branch Stent Graft System
Description: The modular embedded aortic arch stent graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system and the branch stent system.
Study: NCT01254318

Intervention type: OTHER
Intervention: Standard Care
Description: Health-care interventions will be recorded; no additional procedures outside the standard of care will be required.
Study: NCT03659253

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CBO AND BROTHEL-BASED ART SERVICE
Description: The CBOs involved in this intervention are Kebaya and Vesta. Kebaya is an CBO working for Transgender (TG) community. It serves as community gathering place for TG and others, as HIV testing site on regular bases, and also as shelter for homeless HIV patients. The proposed intervention Is that HATI Project will provide HIV testing and treatment in the community, CBO and brothel in collaboration with nearby Puskesmas.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS REMINDER
Description: HATI SMS reminder: short message services as reminders to inform ART patients when to take medication, visit the clinics (1 week before the next visit) and remind if they miss clinic appointment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS REMINDER
Description: HATI SMS reminder: short message services as reminders to inform ART patients when to take medication, visit the clinics (1 week before the next visit) and remind if they miss clinic appointment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS REMINDER
Description: HATI SMS reminder: short message services as reminders to inform ART patients when to take medication, visit the clinics (1 week before the next visit) and remind if they miss clinic appointment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MOTIVATIONAL INTERVIEWING
Description: The approach used in this intervention is an individual counselling with a MI approach, as it is considered a brief form of therapy have been known to be effective in improving HIV treatment adherence.~The sessions will be held from 3 to up to 10 MI counselling over 6-month period of intervention. The goal of this intervention is to help PWID gain an understanding of their medication-taking behaviors and the actions necessary to successfully maintain a high level of adherence

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MOTIVATIONAL INTERVIEWING
Description: The approach used in this intervention is an individual counselling with a MI approach, as it is considered a brief form of therapy have been known to be effective in improving HIV treatment adherence.~The sessions will be held from 3 to up to 10 MI counselling over 6-month period of intervention. The goal of this intervention is to help PWID gain an understanding of their medication-taking behaviors and the actions necessary to successfully maintain a high level of adherence
Study: NCT02177539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclopentolate
Description: Traditional scheme. Cyclopentolate, repeat dosage 5 minutes and then wait 40 minutes to retinoscopy. Total wait 45 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclopentolate
Description: Traditional scheme. Cyclopentolate, repeat dosage 5 minutes and then wait 40 minutes to retinoscopy. Total wait 45 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclopentolate+tropicamide+phenylephrine
Description: New scheme. All drugs together and wait 30 minutes for retinoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclopentolate+tropicamide+phenylephrine
Description: New scheme. All drugs together and wait 30 minutes for retinoscopy